<DOC>
	<DOCNO>NCT01935453</DOCNO>
	<brief_summary>The main purpose study study safety OrienX010 treatment kind solid tumor melanoma , liver cancer , pancreatic cancer lung cancer .</brief_summary>
	<brief_title>A Phase I Study Recombinant hGM-CSF Herpes Simplex Virus Treat Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Herpes Simplex</mesh_term>
	<criteria>patient advance stage malignant tumor diagnosticated pathologic cytological analysis . lack routine effective treatment , failure routine treatment relapse age 1870 , ECOG 02 estimate survival 3 month interval 4 week since exposure chemotherapy radiotherapy 6 week since exposure nitrosoureas mitomycin C. Serious internal disease uncontrolled primary metastatic brain tumor size tumor meet requirement injection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>